Polymorphism ea liphatsa tsa lefutso tsa CYP2C19 tsa motho

CYP2C19 ke e 'ngoe ea li-enzyme tsa bohlokoa tse fetolang metsoako ea lithethefatsi lelapeng la CYP450. Li-substrate tse ngata tsa tlhaho le hoo e ka bang 2% ea meriana ea bongaka li fetoloa metsoako ea CYP2C19, joalo ka metabolism ea li-antiplatelet aggregation inhibitors (joalo ka clopidogrel), li-proton pump inhibitors (omeprazole), li-anticonvulsants, jj. Li-polymorphism tsa liphatsa tsa lefutso tsa CYP2C19 le tsona li na le liphapang bokhoning ba metabolism ba lithethefatsi tse amanang le tsona. Liphetoho tsena tsa lintlha tsa *2 (rs4244285) le *3 (rs4986893) li baka tahlehelo ea ts'ebetso ea enzyme e ngotsoeng ke gene ea CYP2C19 le bofokoli ba bokhoni ba metabolic substrate, 'me li eketsa mahloriso a mali, e le ho baka liketso tse mpe tsa lithethefatsi tse amanang le mahloriso a mali. *17 (rs12248560) e ka eketsa ts'ebetso ea enzyme e ngotsoeng ke gene ea CYP2C19, tlhahiso ea li-metabolites tse sebetsang, le ho ntlafatsa thibelo ea ho bokellana ha li-platelet le ho eketsa kotsi ea ho tsoa mali. Bakeng sa batho ba nang le metabolism e liehang ea lithethefatsi, ho nka litekanyetso tse tloaelehileng ka nako e telele ho tla baka chefo e tebileng le litla-morao tse mpe: haholo-holo tšenyo ea sebete, tšenyo ea tsamaiso ea hematopoietic, tšenyo ea tsamaiso ea methapo e bohareng, jj., e ka lebisang lefung maemong a tebileng. Ho ea ka liphapang tsa motho ka mong metabolism ea lithethefatsi e tsamaellanang, hangata e arotsoe ka mefuta e mene ea phenotypes, e leng metabolism e potlakileng haholo (UM,*17/*17,*1/*17), metabolism e potlakileng (RM,*1/*1), metabolism e mahareng (IM, *1/*2, *1/*3), metabolism e liehang (PM, *2/*2, *2/*3, *3/*3).